Successful treatment of severe MSUD in Bckdhb −/− mice with neonatal AAV gene therapy
Journal of Inherited Metabolic Disease · 2024
DOI: 10.1002/jimd.12604 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Inherited Metabolic Disease, 2024. Verfasst von Clément Pontoizeau und 15 weiteren Autor:innen. Beteiligte Einrichtung: Necker Hospital, APHP, Biochemistry, Metabolomics Unit, University Paris Cité, Paris, France. Hauptthemen laut MEDLINE: Maple Syrup Urine Disease. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conseil Régional, Île-de-France.
Abstract (Originalsprache)
Maple syrup urine disease (MSUD) is rare autosomal recessive metabolic disorder caused by the dysfunction of the mitochondrial branched‐chain 2‐ketoacid dehydrogenase (BCKD) enzyme complex leading to massive accumulation of branched‐chain amino acids and 2‐keto acids. MSUD management, based on a life‐long strict protein restriction with nontoxic amino acids oral supplementation represents an unmet need as it is associated with a poor quality of life, and does not fully protect from acute life‐threatening decompensations or long‐term neuropsychiatric complications. Orthotopic liver transplantation is a beneficial therapeutic option, which shows that restoration of only a fraction of whole‐body BCKD enzyme activity is therapeutic. MSUD is thus an ideal target for gene therapy. We and others have tested AAV gene therapy in mice for two of the three genes involved in MSUD, BCKDHA and DBT . In this study, we developed a similar approach for the third MSUD gene, BCKDHB . We performed the first characterization of a Bckdhb −/− mouse model, which recapitulates the severe human phenotype of MSUD with early‐neonatal symptoms leading to death during the first week of life with massive accumulation of MSUD biomarkers. Based on our previous experience in Bckdha −/− mice, we designed a transgene carrying the human BCKDHB gene under the control of a ubiquitous EF1α promoter, encapsidated in an AAV8 capsid. Injection in neonatal Bckdhb −/− mice at 10 14 vg/kg achieved long‐term rescue of the severe MSUD phenotype of Bckdhb −/− mice. These data further validate the efficacy of gene therapy for MSUD opening perspectives towards clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Necker Hospital, APHP, Biochemistry, Metabolomics Unit, University Paris Cité, Paris, France.
- Necker Hospital, APHP, Reference Center for Inborn Error of Metabolism, Pediatrics Department, University Paris Cité, Paris, France.
- Inserm UMR_S1163, Institut Imagine, Paris, France.
- Généthon INTEGRARE UMR-S951, University of Evry, Evry, France.
- CRSA, St Antoine Hospital, Paris, France.
- Inserm U1151, Institut Necker Enfants Malades, Paris, France.
ORCID-Profile: Manuel Schiff
Förderung
- Conseil Régional, Île-de-France
Zitieren
APA
Pontoizeau, C., Gaborit, C., Tual, N., Simon-Sola, M., Rotaru, I., Benoist, M., Colella, P., Lamazière, A., Brassier, A., Arnoux, J. B., Rötig, A., Ottolenghi, C., de Lonlay, P., Mingozzi, F., Cavazzana, M., & Schiff, M. (2024). Successful treatment of severe MSUD in Bckdhb −/− mice with neonatal AAV gene therapy. Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.12604
Vancouver
Pontoizeau C, Gaborit C, Tual N, Simon-Sola M, Rotaru I, Benoist M, et al. Successful treatment of severe MSUD in Bckdhb −/− mice with neonatal AAV gene therapy. Journal of Inherited Metabolic Disease. 2024. doi:10.1002/jimd.12604
BibTeX
@article{Pontoizeau2024,
author = {Pontoizeau, Clément and Gaborit, Clovis and Tual, Nolan and Simon-Sola, Marcelo and Rotaru, Irina and Benoist, Marion and Colella, Pasqualina and Lamazière, Antonin and Brassier, Anaïs and Arnoux, Jean-Baptiste and Rötig, Agnès and Ottolenghi, Chris and de Lonlay, Pascale and Mingozzi, Federico and Cavazzana, Marina and Schiff, Manuel},
title = {Successful treatment of severe MSUD in Bckdhb −/− mice with neonatal AAV gene therapy},
journal = {Journal of Inherited Metabolic Disease},
year = {2024},
doi = {10.1002/jimd.12604}
}
EUVIMED